3.4. Best practices for human subjects protection
As guidance continues to be developed, some best practices are coming
to light in the field. Two of the coauthors (Campbell &Miele) of this
paper were investigators in a randomized, multisite clinical trial studying
the effectiveness of aweb-based psychosocial intervention for SUDs.
Given that e-technology was being used as an intervention, the researchers
proposed using electronic communication tools (email,
texting, and Facebook) for participant location and follow-up (see
[22–25] for methods and primary outcomes, respectively). At the time
of the study (2010–2012), few IRBs had guidance about using social
media and electronic communication in research, but use of social
media and e-technology was becoming more common among participants.
Three of 10 sites used electronic communication in this capacity.
Research teams developed their own procedures and recommendations
for review. The most important component of each policy was protection
of human subjects, especially confidentiality. Based on these experiences
and emerging developments in the field, the authors provide
some recommendations for using e-technology in clinical trials while
protecting participants (see Fig. 3).
3.4. Best practices for human subjects protectionAs guidance continues to be developed, some best practices are comingto light in the field. Two of the coauthors (Campbell &Miele) of thispaper were investigators in a randomized, multisite clinical trial studyingthe effectiveness of aweb-based psychosocial intervention for SUDs.Given that e-technology was being used as an intervention, the researchersproposed using electronic communication tools (email,texting, and Facebook) for participant location and follow-up (see[22–25] for methods and primary outcomes, respectively). At the timeof the study (2010–2012), few IRBs had guidance about using socialmedia and electronic communication in research, but use of socialmedia and e-technology was becoming more common among participants.Three of 10 sites used electronic communication in this capacity.Research teams developed their own procedures and recommendationsfor review. The most important component of each policy was protectionof human subjects, especially confidentiality. Based on these experiencesand emerging developments in the field, the authors providesome recommendations for using e-technology in clinical trials whileprotecting participants (see Fig. 3).
การแปล กรุณารอสักครู่..
